Experimental subjects
first-ever, epilepsy, stroke, brain injury, liver and kidney insufficiency, Parkinson’s disease, cardiopulmonary insufficiency, trauma
MALIGNANT TUMOUR, EPILEPSY, STROKE, ENCEPHALITIS, MAY, HAEMORRHAGIC STROKE, HYPERTENSION
A single-blinded, randomized controlled clinical trial (RCT) was conducted. Subjects were recruited from the Center of Rehabilitation Medicine, The Second Hospital of Jiaxing from May 2021 to August 2022. They chose whether to participate in this study after learning about the procedures and the potential consequences. Then, to determine eligibility, more specific information was gathered. The inclusion criteria were as follows: 40–75 years old; first-ever ischaemic or haemorrhagic stroke diagnosed by computed tomography (CT) or magnetic resonance imaging (MRI); 1–6 months after stroke onset; no history of previous brain injury; MMSE score of 23 points; and ability rto stand alone. Patients with a history of epilepsy, brain trauma, Parkinson’s disease, or encephalitis; severe cardiopulmonary insufficiency, liver and kidney insufficiency, malignant tumour, or malignant progressive hypertension; inability to understand/execute commands; and a history of musculoskeletal surgery on either lower extremity were excluded. The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Hospital of Jiaxing (reference number: JXEY-2021SZ045). The patients/participants provided their written informed consent prior to participation in this study.